Journal of cachexia, sarcopenia and muscle · 2026
Frailty and Recurrent Cardiovascular Events in Patients With Obstructive Sleep Apnoea: The SAVE Study.
СтатьяРандомизированное исследованиеМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
You Shoujiang, Zheng Danni, Harris Katie, Loffler Kelly A, McEvoy R Doug, Peters Ruth, Li Qiang, Barbé Ferran, Chen Linan, Chen Xiaoying, Cao Yongjun, Liu Chun-Feng, Lorenzi-Filho Geraldo, Woodward Mark, Chalmers John, Anderson Craig S, SAVE Investigators
Аннотация
BACKGROUND: Frailty is a common syndrome in patients with cardiovascular disease (CVD). Whether frailty modifies the risk of recurrent cardiovascular events in patients with established CVD and obstructive sleep apnoea (OSA) is uncertain. We aimed to determine associations of frailty and the risk of recurrent cardiovascular events in adults with moderate-severe OSA and established CVD.
METHODS: Post hoc analyses of the international Sleep Apnea Cardiovascular Endpoints (SAVE) trial where participants from 89 clinical centres in seven countries with moderate-to-severe OSA and established CVD were randomised to usual care plus continuous positive airway pressure (CPAP) treatment or usual care alone. Participants were categorised using the Rockwood frailty index (FI) into three groups: nonfrail (FI ≤ 0.210), moderately frail (FI 0.211-0.310) and severely frail (FI ≥ 0.311). Cox proportional hazards models were used to assess associations of FI and both composite and individual cardiovascular outcomes over an average follow-up period of 3.7 years.
RESULTS: There were 2653 OSA participants (mean age 61.3 [SD 7.8] years, and 507 [19.1%] were female) with established CVD included with a mean FI of 0.290 (SD 0.125). There were 783 (29.5%) and 1006 (37.9%) classified as moderately and severely frail, respectively. Compared to those without frailty, those with severe frailty had increased risks of the composite cardiovascular endpoint (hazard ratio [HR], 2.41; 95% confidence interval [CI], 1.88-3.11), and separately for stroke (HR, 2.40; 95% CI, 1.54-3.74), hospitalisation for unstable angina (HR, 2.94; 95% CI, 1.98-4.35), all-cause mortality (HR, 1.77; 95% CI, 1.01-3.11) and CVD death (HR, 2.51; 95% CI, 1.13-5.60), during a mean 3.7 years of follow-up. There was a similar level of adherence to CPAP treatment (p = 0.488) across baseline frailty groups and no heterogeneity in the effect of CPAP treatment on composite and separate cardiovascular events.
CONCLUSIONS: In the SAVE cohort of adults with co-occurring OSA and CVD, a higher FI was associated with significantly higher risk of recurrent cardiovascular events. Frailty did not modify CPAP treatment adherence or the effect of CPAP on recurrent cardiovascular events.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00738179.
METHODS: Post hoc analyses of the international Sleep Apnea Cardiovascular Endpoints (SAVE) trial where participants from 89 clinical centres in seven countries with moderate-to-severe OSA and established CVD were randomised to usual care plus continuous positive airway pressure (CPAP) treatment or usual care alone. Participants were categorised using the Rockwood frailty index (FI) into three groups: nonfrail (FI ≤ 0.210), moderately frail (FI 0.211-0.310) and severely frail (FI ≥ 0.311). Cox proportional hazards models were used to assess associations of FI and both composite and individual cardiovascular outcomes over an average follow-up period of 3.7 years.
RESULTS: There were 2653 OSA participants (mean age 61.3 [SD 7.8] years, and 507 [19.1%] were female) with established CVD included with a mean FI of 0.290 (SD 0.125). There were 783 (29.5%) and 1006 (37.9%) classified as moderately and severely frail, respectively. Compared to those without frailty, those with severe frailty had increased risks of the composite cardiovascular endpoint (hazard ratio [HR], 2.41; 95% confidence interval [CI], 1.88-3.11), and separately for stroke (HR, 2.40; 95% CI, 1.54-3.74), hospitalisation for unstable angina (HR, 2.94; 95% CI, 1.98-4.35), all-cause mortality (HR, 1.77; 95% CI, 1.01-3.11) and CVD death (HR, 2.51; 95% CI, 1.13-5.60), during a mean 3.7 years of follow-up. There was a similar level of adherence to CPAP treatment (p = 0.488) across baseline frailty groups and no heterogeneity in the effect of CPAP treatment on composite and separate cardiovascular events.
CONCLUSIONS: In the SAVE cohort of adults with co-occurring OSA and CVD, a higher FI was associated with significantly higher risk of recurrent cardiovascular events. Frailty did not modify CPAP treatment adherence or the effect of CPAP on recurrent cardiovascular events.
TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT00738179.